Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408215 | 0.81 | CYP2C19 (0.47) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL7410847 | 0.81 | CYP2C19 (0.47) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL25597428 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL6654265 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL | |
| SCHEMBL9807067 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL | |
| SCHEMBL8874259 | 0.78 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL4634087 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL | |
| SCHEMBL9327734 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL | |
| SCHEMBL9807069 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL | |
| SCHEMBL4634083 | 0.78 | ALDH1A1 (0.50) | CTSKACE2ALDH1A1CTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | disclosed |
| US-6462023-B1 | SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2002-10-08 | — | — | US | disclosed |
| EP-0925278-B1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARM (GB) | 2002-07-17 | — | — | EP | disclosed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | disclosed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |